ClinicalTrials.gg
RecruitingNCT07474428Updated Oct 22, 2026

Quality of Life in Pediatric Participants With HHT

An observational study in Hereditary Haemorrhagic Telangiectasia (HHT), sponsored by Ashley Nelson. Recruiting at 1 site in United States. Open to participants aged 2 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Ashley Nelson · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 22, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
70
Ages
2 Years to 25 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States — 5 open to participants now, 8 under way, 1 of them phase 3. Telangiectasia, Hereditary Hemorrhagic · United States.

Started
2026
with 2 others
Observational
9 of 29
2 open now
Registered
26th of 29
by date
Lead sponsor
1 of 29
Ashley Nelson

Among the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, this one is one of 3 that started in 2026, is one of 9 observational ones, and was the 26th registered.

Telangiectasia, Hereditary Hemorrhagic

106 studies on the registry are indexed under Telangiectasia, Hereditary Hemorrhagic; 24 are open to participants now.

Browse Telangiectasia, Hereditary Hemorrhagic studies →

Open to participants now

5 of the 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Telangiectasia, Hereditary Hemorrhagic studies recruiting now, 14 (82%) set no upper age limit and 2 (12%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 2 Years to 25 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Telangiectasia, Hereditary Hemorrhagic with a site in United States, or all of them as a file.
02

Study summary

This observational study evaluates health-related quality of life (HR-QoL) in pediatric and young adult patients aged 2-25 years with Hereditary Hemorrhagic Telangiectasia (HHT). Eligible participants are patients receiving care at Cincinnati Children's Hospital Medical Center and / or their caregivers. Participants will complete validated quality-of-life questionnaires assessing physical, emotional, social, and disease-specific functioning over the past 30 days. A paired retrospective chart review will assess disease severity and clinical utilization, including procedures and imaging studies. The primary objective is to describe mean QoL scores for this population. Secondary objectives include evaluating associations between QoL scores, disease severity, and clinical utilization.

03

Conditions studied

  • Hereditary Haemorrhagic Telangiectasia (HHT)

Keywords

  • HHT
  • QOL
  • Pedatric
04

Who can participate

Ages eligible
2 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include pediatric and young adult patients aged 2-25 years with a confirmed diagnosis of Hereditary Hemorrhagic Telangiectasia receiving care at Cincinnati Children's Hospital Medical Center. Eligible participants will be identified through the electronic medical record based on diagnostic criteria and clinic records. Both caregiver proxy respondents (for children aged 2-17 years) and patient self-report respondents (for individuals aged 8-25 years) will be included. Participants will complete validated quality-of-life questionnaires assessing health-related and disease-specific quality of life over the prior 30 days. A paired retrospective chart review will be conducted to obtain clinical variables including disease severity, procedures, imaging studies, and other healthcare utilization measures associated with HHT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Patient aged 2-25 years with a confirmed (either genetic or clinical) diagnosis of definite HHT

      • Parent or legal guardian willing and able to complete the caregiver survey for patients aged 2-17.
      • For patients >18, willing and able to complete the patient survey.
      • Receipt of care through CCHMC (at least one visit with genetic counselor or director of HHT Center)
      • Ability to complete survey in English
      • For self-report: patient age greater than or equal to 8 years old that assent to survey.

Exclusion criteria

Exclusion Criteria:

  • Patients that are older than 25 years old.
  • Patients that are younger than 2 years old.
  • Individuals without definite HHT diagnosis.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
70 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. PedsQL Total Score

    Mean total health-related quality of life score measured using the Pediatric Quality of Life Inventory (PedsQL). Scores range from 0-100, with lower scores indicating worse quality of life.

    Time frame: 30 days

  2. HHT-QOL

    Mean score ranging from 0-16 assessing HHT-related symptom burden and functional impact. Higher scores indicate worse impairment.

    Time frame: past 30 days

Secondary outcomes

  1. Epistaxis Severity Score

    Continuous score (0-10) measuring nosebleed severity. Higher scores indicate more severe epistaxis.

    Time frame: past 30 days

  2. HHT Severity Score

    Continuous score ranging 0-7 reflecting lifetime disease severity based on organ AVMs and bleeding history.

    Time frame: lifetime

  3. Clinical Utilization

    Number of procedures (embolization, cauterization) and imaging studies (MRI, CT, bubble echocardiography).

    Time frame: lifetime

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gong AJ, Bolsegui ML, Lee EE, Mathai SC, Weiss CR. Assessing the Psychometric Validity of the Epistaxis Severity Score: Internal Consistency and Test-Retest Reliability. Am J Rhinol Allergy. 2024 Jan;38(1):38-46. doi: 10.1177/19458924231207137. Epub 2023 Oct 11. PubMed 37822162 ↗
  • Blivet S, Cobarzan D, Beauchet A, El Hajjam M, Lacombe P, Chinet T. Impact of pulmonary arteriovenous malformations on respiratory-related quality of life in patients with hereditary haemorrhagic telangiectasia. PLoS One. 2014 Mar 6;9(3):e90937. doi: 10.1371/journal.pone.0090937. eCollection 2014. PubMed 24603803 ↗
  • Beslow LA, Breimann J, Licht DJ, Waldman J, Fallacaro S, Pyeritz RE, Goldmuntz E, Vossough A. Cerebrovascular Malformations in a Pediatric Hereditary Hemorrhagic Telangiectasia Cohort. Pediatr Neurol. 2020 Sep;110:49-54. doi: 10.1016/j.pediatrneurol.2020.05.008. Epub 2020 May 25. PubMed 32718529 ↗
  • Beckman JD, Li Q, Hester ST, Leitner O, Smith KL, Kasthuri RS. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding. Orphanet J Rare Dis. 2020 Jul 13;15(1):185. doi: 10.1186/s13023-020-01453-1. PubMed 32660636 ↗
  • Al-Samkari H, Thomas SM, Marsh D, Kasthuri RS, Iyer VN, Pishko AM, Decker JE, Weiss CR, Whitehead KJ, Conrad MB, Zumberg MS, Zhou JY, Parambil J, Carper B, Clancy M, McCrae KR. Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia. Blood Adv. 2026 May 12;10(9):2967-2976. doi: 10.1182/bloodadvances.2025019484. PubMed 41719457 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Dec 2026, 3 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Sep 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 16, 2026
StartActual
Sep 1, 2026was Jul 2026
Primary completionEst.
Dec 2026
CompletionEst.
Aug 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
Cincinnati Children's Hospital Medical Center is now Recruiting
Oct 22, 2026
Start date
Jul 2026→Sep 1, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    Cincinnati Children's Hospital Medical Center is now Recruiting
    Start date Jul 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07474428
Lead sponsor
Ashley Nelson
Responsible party
Ashley Nelson (Sponsor-Investigator, Children's Hospital Medical Center, Cincinnati) — Sponsor-investigator
First posted
Mar 16, 2026
Start date
Sep 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Aug 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Katie Wusik, Master of Genetic Counseling
Contact
katie.wusik@cchmc.org
(513) 636-3200
Ashley Nelson
Contact
ashley.nelson@cchmc.org

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion